Characteristics and outcomes of HFpEF with declining ejection fraction

Jin Joo Park, Chan Soon Park, Alexandre Mebazaa, Il Young Oh, Hyun Ah Park, Hyun Jai Cho, Hae Young Lee, Kye Hun Kim, Byung Su Yoo, Seok Min Kang, Sang Hong Baek, Eun Seok Jeon, Jae Joong Kim, Myeong Chan Cho, Shung Chull Chae, Byung Hee Oh, Dong Ju Choi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Some patients with heart failure with preserved ejection fraction (HFpEF) experience declining of left-ventricular ejection fraction (LVEF) during follow-up. We aim to investigate the characteristics and outcomes of patients with HF with declining ejection fraction (HFdEF). Methods: We analyzed a prospective, nationwide multicenter cohort with consecutive patients with acute HF enrolled from March 2011 to December 2014. HFpEF was defined as LVEF ≥ 50% at index admission. After 1 year, HFpEF patients were further classified as HFdEF (LVEF ≥ 50% at admission and < 50% at 1 year), and persistent HFpEF (LVEF ≥ 50% both at admission and 1 year). Primary outcome was 4-year all-cause mortality according to HF type from HFdEF diagnosis. Results: Of patients with HFpEF, 426 (90.4%) were diagnosed as having persistent HFpEF and 45 (9.6%) as having HFdEF. Natriuretic peptide level was an independent predictor of HFdEF (natriuretic peptide level > median: odds ratio: 3.20, 95% confidence interval [CI]: 1.42–7.25, P = 0.005). During 4-year follow-up, patients with HFdEF had higher mortality than those with persistent HFpEF (Log-rank P < 0.001). After adjustment, HFdEF was associated with an almost twofold increased risk for mortality (hazard ratio 1.82, 95% CI 1.13–2.96, P = 0.015). The use of beta-blockers, renin–angiotensin system inhibitors, and mineralocorticoid receptor antagonists was not associated with improved prognosis of patients with HFdEF. Conclusions: HFdEF is a distinct HF type with grave outcomes. Further investigations that focus on HFdEF are warranted to better understand and develop treatment strategies for these high-risk patients. Clinical trial registration: ClinicalTrial.gov identifier: NCT01389843. URL: https://clinicaltrials.gov/ct2/show/NCT01389843.

Original languageEnglish
Pages (from-to)225-234
Number of pages10
JournalClinical Research in Cardiology
Volume109
Issue number2
DOIs
StatePublished - 1 Feb 2020

Fingerprint

Heart Failure
Stroke Volume
Confidence Intervals
Mineralocorticoid Receptor Antagonists
Mortality
Odds Ratio
Clinical Trials

Keywords

  • Heart failure with declining ejection fraction
  • Mortality
  • Predictor
  • Prognosis
  • Treatment

Cite this

Park, Jin Joo ; Park, Chan Soon ; Mebazaa, Alexandre ; Oh, Il Young ; Park, Hyun Ah ; Cho, Hyun Jai ; Lee, Hae Young ; Kim, Kye Hun ; Yoo, Byung Su ; Kang, Seok Min ; Baek, Sang Hong ; Jeon, Eun Seok ; Kim, Jae Joong ; Cho, Myeong Chan ; Chae, Shung Chull ; Oh, Byung Hee ; Choi, Dong Ju. / Characteristics and outcomes of HFpEF with declining ejection fraction. In: Clinical Research in Cardiology. 2020 ; Vol. 109, No. 2. pp. 225-234.
@article{84c610e6b6be4eff90e45f4573d018c4,
title = "Characteristics and outcomes of HFpEF with declining ejection fraction",
abstract = "Objective: Some patients with heart failure with preserved ejection fraction (HFpEF) experience declining of left-ventricular ejection fraction (LVEF) during follow-up. We aim to investigate the characteristics and outcomes of patients with HF with declining ejection fraction (HFdEF). Methods: We analyzed a prospective, nationwide multicenter cohort with consecutive patients with acute HF enrolled from March 2011 to December 2014. HFpEF was defined as LVEF ≥ 50{\%} at index admission. After 1 year, HFpEF patients were further classified as HFdEF (LVEF ≥ 50{\%} at admission and < 50{\%} at 1 year), and persistent HFpEF (LVEF ≥ 50{\%} both at admission and 1 year). Primary outcome was 4-year all-cause mortality according to HF type from HFdEF diagnosis. Results: Of patients with HFpEF, 426 (90.4{\%}) were diagnosed as having persistent HFpEF and 45 (9.6{\%}) as having HFdEF. Natriuretic peptide level was an independent predictor of HFdEF (natriuretic peptide level > median: odds ratio: 3.20, 95{\%} confidence interval [CI]: 1.42–7.25, P = 0.005). During 4-year follow-up, patients with HFdEF had higher mortality than those with persistent HFpEF (Log-rank P < 0.001). After adjustment, HFdEF was associated with an almost twofold increased risk for mortality (hazard ratio 1.82, 95{\%} CI 1.13–2.96, P = 0.015). The use of beta-blockers, renin–angiotensin system inhibitors, and mineralocorticoid receptor antagonists was not associated with improved prognosis of patients with HFdEF. Conclusions: HFdEF is a distinct HF type with grave outcomes. Further investigations that focus on HFdEF are warranted to better understand and develop treatment strategies for these high-risk patients. Clinical trial registration: ClinicalTrial.gov identifier: NCT01389843. URL: https://clinicaltrials.gov/ct2/show/NCT01389843.",
keywords = "Heart failure with declining ejection fraction, Mortality, Predictor, Prognosis, Treatment",
author = "Park, {Jin Joo} and Park, {Chan Soon} and Alexandre Mebazaa and Oh, {Il Young} and Park, {Hyun Ah} and Cho, {Hyun Jai} and Lee, {Hae Young} and Kim, {Kye Hun} and Yoo, {Byung Su} and Kang, {Seok Min} and Baek, {Sang Hong} and Jeon, {Eun Seok} and Kim, {Jae Joong} and Cho, {Myeong Chan} and Chae, {Shung Chull} and Oh, {Byung Hee} and Choi, {Dong Ju}",
year = "2020",
month = "2",
day = "1",
doi = "10.1007/s00392-019-01505-y",
language = "English",
volume = "109",
pages = "225--234",
journal = "Clinical Research in Cardiology",
issn = "1861-0684",
publisher = "D. Steinkopff-Verlag",
number = "2",

}

Park, JJ, Park, CS, Mebazaa, A, Oh, IY, Park, HA, Cho, HJ, Lee, HY, Kim, KH, Yoo, BS, Kang, SM, Baek, SH, Jeon, ES, Kim, JJ, Cho, MC, Chae, SC, Oh, BH & Choi, DJ 2020, 'Characteristics and outcomes of HFpEF with declining ejection fraction', Clinical Research in Cardiology, vol. 109, no. 2, pp. 225-234. https://doi.org/10.1007/s00392-019-01505-y

Characteristics and outcomes of HFpEF with declining ejection fraction. / Park, Jin Joo; Park, Chan Soon; Mebazaa, Alexandre; Oh, Il Young; Park, Hyun Ah; Cho, Hyun Jai; Lee, Hae Young; Kim, Kye Hun; Yoo, Byung Su; Kang, Seok Min; Baek, Sang Hong; Jeon, Eun Seok; Kim, Jae Joong; Cho, Myeong Chan; Chae, Shung Chull; Oh, Byung Hee; Choi, Dong Ju.

In: Clinical Research in Cardiology, Vol. 109, No. 2, 01.02.2020, p. 225-234.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Characteristics and outcomes of HFpEF with declining ejection fraction

AU - Park, Jin Joo

AU - Park, Chan Soon

AU - Mebazaa, Alexandre

AU - Oh, Il Young

AU - Park, Hyun Ah

AU - Cho, Hyun Jai

AU - Lee, Hae Young

AU - Kim, Kye Hun

AU - Yoo, Byung Su

AU - Kang, Seok Min

AU - Baek, Sang Hong

AU - Jeon, Eun Seok

AU - Kim, Jae Joong

AU - Cho, Myeong Chan

AU - Chae, Shung Chull

AU - Oh, Byung Hee

AU - Choi, Dong Ju

PY - 2020/2/1

Y1 - 2020/2/1

N2 - Objective: Some patients with heart failure with preserved ejection fraction (HFpEF) experience declining of left-ventricular ejection fraction (LVEF) during follow-up. We aim to investigate the characteristics and outcomes of patients with HF with declining ejection fraction (HFdEF). Methods: We analyzed a prospective, nationwide multicenter cohort with consecutive patients with acute HF enrolled from March 2011 to December 2014. HFpEF was defined as LVEF ≥ 50% at index admission. After 1 year, HFpEF patients were further classified as HFdEF (LVEF ≥ 50% at admission and < 50% at 1 year), and persistent HFpEF (LVEF ≥ 50% both at admission and 1 year). Primary outcome was 4-year all-cause mortality according to HF type from HFdEF diagnosis. Results: Of patients with HFpEF, 426 (90.4%) were diagnosed as having persistent HFpEF and 45 (9.6%) as having HFdEF. Natriuretic peptide level was an independent predictor of HFdEF (natriuretic peptide level > median: odds ratio: 3.20, 95% confidence interval [CI]: 1.42–7.25, P = 0.005). During 4-year follow-up, patients with HFdEF had higher mortality than those with persistent HFpEF (Log-rank P < 0.001). After adjustment, HFdEF was associated with an almost twofold increased risk for mortality (hazard ratio 1.82, 95% CI 1.13–2.96, P = 0.015). The use of beta-blockers, renin–angiotensin system inhibitors, and mineralocorticoid receptor antagonists was not associated with improved prognosis of patients with HFdEF. Conclusions: HFdEF is a distinct HF type with grave outcomes. Further investigations that focus on HFdEF are warranted to better understand and develop treatment strategies for these high-risk patients. Clinical trial registration: ClinicalTrial.gov identifier: NCT01389843. URL: https://clinicaltrials.gov/ct2/show/NCT01389843.

AB - Objective: Some patients with heart failure with preserved ejection fraction (HFpEF) experience declining of left-ventricular ejection fraction (LVEF) during follow-up. We aim to investigate the characteristics and outcomes of patients with HF with declining ejection fraction (HFdEF). Methods: We analyzed a prospective, nationwide multicenter cohort with consecutive patients with acute HF enrolled from March 2011 to December 2014. HFpEF was defined as LVEF ≥ 50% at index admission. After 1 year, HFpEF patients were further classified as HFdEF (LVEF ≥ 50% at admission and < 50% at 1 year), and persistent HFpEF (LVEF ≥ 50% both at admission and 1 year). Primary outcome was 4-year all-cause mortality according to HF type from HFdEF diagnosis. Results: Of patients with HFpEF, 426 (90.4%) were diagnosed as having persistent HFpEF and 45 (9.6%) as having HFdEF. Natriuretic peptide level was an independent predictor of HFdEF (natriuretic peptide level > median: odds ratio: 3.20, 95% confidence interval [CI]: 1.42–7.25, P = 0.005). During 4-year follow-up, patients with HFdEF had higher mortality than those with persistent HFpEF (Log-rank P < 0.001). After adjustment, HFdEF was associated with an almost twofold increased risk for mortality (hazard ratio 1.82, 95% CI 1.13–2.96, P = 0.015). The use of beta-blockers, renin–angiotensin system inhibitors, and mineralocorticoid receptor antagonists was not associated with improved prognosis of patients with HFdEF. Conclusions: HFdEF is a distinct HF type with grave outcomes. Further investigations that focus on HFdEF are warranted to better understand and develop treatment strategies for these high-risk patients. Clinical trial registration: ClinicalTrial.gov identifier: NCT01389843. URL: https://clinicaltrials.gov/ct2/show/NCT01389843.

KW - Heart failure with declining ejection fraction

KW - Mortality

KW - Predictor

KW - Prognosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85068735581&partnerID=8YFLogxK

U2 - 10.1007/s00392-019-01505-y

DO - 10.1007/s00392-019-01505-y

M3 - Article

AN - SCOPUS:85068735581

VL - 109

SP - 225

EP - 234

JO - Clinical Research in Cardiology

JF - Clinical Research in Cardiology

SN - 1861-0684

IS - 2

ER -